Detection of S100B, S100A6 and galectin-3 ligands in meningiomas as markers of aggressiveness.
The biological factors responsible for the increased aggressiveness in atypical meningiomas are not well known. The aim of this study is to evaluate the discriminatory value of a number of biological markers (S100 proteins and galectin-3 and its ligand profile) with respect to benign and atypical meningiomas. Using 63 meningiomas (39 benign and 24 atypical), we performed a semi-quantitative histochemical analysis of both the expression of galectin-3 and its ligand profile and the Ca2+-binding proteins S100A5, S100A6 and S100B. Three features were considered for each marker, namely the labeling index (LI), the staining intensity (SI) and the global score (LI + SI). A low S100A6 labeling index was observed in 51% of the benign and 25% of the atypical meningiomas (P=0.035). Furthermore, high S100B scores were observed in 46% of the benign and in only 8% of the atypical meningiomas (P=0.001). Seventy-one percent of the atypical meningiomas exhibited a low level of staining intensity for the galectin-3-binding sites as compared to only 36% of the benign meningiomas (P=0.007). The combination of these three markers (by means of a decision tree) enabled an improved discriminatory criterion to be established between the benign and the atypical meningiomas. Our results thus suggest that the galectin-3-binding sites and S100B (and S100A6 to a lesser extent) could play a role in the aggressiveness characterizing atypical meningiomas.
Hancq
Sabine
S
Department of Neurosurgery, Erasmus University Hospital, Brussels, Belgium.
Salmon
Isabelle
I
Brotchi
Jacques
J
Gabius
Hans-Joachim
HJ
Heizmann
Claus W
CW
Kiss
Robert
R
Decaestecker
Christine
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001324:Autoantigens; D015415:Biomarkers / Q000032:analysis*; D018797:Cell Cycle Proteins / Q000032:analysis* / Q000096:biosynthesis; D003663:Decision Trees; D004815:Epidermal Growth Factor / Q000032:analysis* / Q000096:biosynthesis; D005260:Female; D037502:Galectin 3 / Q000032:analysis* / Q000096:biosynthesis; D006801:Humans; D007150:Immunohistochemistry; D008024:Ligands; D008297:Male; D008577:Meningeal Neoplasms / Q000235:genetics* / Q000473:pathology*; D008579:Meningioma / Q000235:genetics* / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D009414:Nerve Growth Factors / Q000032:analysis* / Q000096:biosynthesis; D011379:Prognosis; D000075383:S100 Calcium Binding Protein A6; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000032:analysis* / Q000096:biosynthesis
D001324:Autoantigens; D015415:Biomarkers; D018797:Cell Cycle Proteins; D037502:Galectin 3; D008024:Ligands; D009414:Nerve Growth Factors; D000075383:S100 Calcium Binding Protein A6; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human; C055351:S100A6 protein, human; D004815:Epidermal Growth Factor